Truist raised the firm’s price target on Intuitive Surgical to $390 from $375 and keeps a Buy rating on the shares as part of a broader research note, turning more positive on the MedTech industry heading into FY24. The firm is citing dwindling recession fears, a downward interest rate bias/perception, a “more pragmatic” view toward the GLP1 overhang/impact, and an attractive sector growth profile for MedTech next year. After a “tough” 2023 in healthcare, MedTech could be a relative destination for funds within healthcare and even “inter-sector” as a “beta/growth” segment that underperformed, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ISRG:
- Johnson & Johnson Stock (NYSE:JNJ): A Smart Dividend Pick for 2024
- Intuitive Surgical price target raised by $55 at Truist, here’s why
- Citi entering 2024 ‘cautiously optimistic’ on U.S. MedTech companies
- Intuitive Surgical price target raised to $330 from $300 at Morgan Stanley
- Robotics Stocks: Bot is Man’s Best Friend